PR83661

TAIPEI, April 14, 2020 /PRNewswire=KYODO JBN/ --

ACRO Biomedical Co., Ltd., the first company in the world to utilize

"supercritical CO2 extraction technology" on cleansing animal tissues and

organs, is gradually showing impressive results on the global patent map. In

2019, ACRO acquired two patents from Japan. One for the decellularized

cartilage graft, and another for the decellularized cornea. The great news

continues with ACRO acquiring patents from the USA and Korea successively for

the decellularized cornea in March 2020.

ACRO has acquired patents from Taiwan, the USA, Japan, and Korea for the

preparation of acellular corneas by utilizing supercritical CO2 extraction

technology. Patents from India, EU, Hong Kong, and mainland China are also on

their way. The wish to benefit patients around the world with damaged cornea is

very promising.

The CEO of ACRO Biomedical, DJ Hsieh, said that the traditional way to utilize

supercritical CO2 extraction technology is to extract herbal medicine and

essential oil. After many years of research and development, ACRO has

successfully utilized the technology on cleansing animal tissues and organs

including skin, bone, cartilage, cornea, blood vessel, nerve, heart, kidney,

liver, pancreas, and brain. Many of the products have received approval from

USFDA, Singapore, Vietnam, Philippines, and Taiwan FDA. Furthermore, ACRO has

licensed out Collagen Ophthalmic Matrix to Oculus BioMed from Australia, and

also signed an exclusive strategic partnership agreement with Marubeni

Corporation from Japan, laying the foundation for the global market.

The advantages of ACRO's technology application are its high efficiency, low

cost, time-saving, and when compared with other products of the same type that

are decellularized with acid-base solutions or organic solvents, it greatly

reduces the chance of allergy and immune rejection. It is a great help for the

future development of the global regenerative medicine.

SOURCE ACRO Biomedical Co., Ltd.